製品の概要

  • 製品名Anti-TCF7L2 antibody
    TCF7L2 一次抗体 製品一覧
  • 製品の詳細
    Mouse monoclonal to TCF7L2
  • アプリケーション適用あり: WBmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Recombinant full length protein, corresponding to amino acids 1-456 of Human TCF7L2

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab57679 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB
  • 追加情報WB: Use at a concentration of 1-5 µg/ml.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine.
    • 組織特異性Detected in epithelium from small intestine, with the highest expression at the top of the crypts and a gradient of expression from crypt to villus. Detected in colon epithelium and colon cancer, and in epithelium from mammary gland and carcinomas derived therefrom.
    • 関連疾患Note=Constitutive activation and subsequent transactivation of target genes may lead to the maintenance of stem-cell characteristics (cycling and longevity) in cells that should normally undergo terminal differentiation and constitute the primary transforming event in colorectal cancer (CRC).
      Genetic variations in TCF7L2 are associated with susceptibility to non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance.
    • 配列類似性Belongs to the TCF/LEF family.
      Contains 1 HMG box DNA-binding domain.
    • 発生段階Highly expressed in crypt regions and barely detectable in villi in epithelium from fetal small intestine at week 16. At week 22 expression in villi had increased strongly.
    • ドメインThe promoter-specific activation domain interacts with the transcriptional coactivator EP300.
    • 翻訳後修飾In vitro, phosphorylated by TNIK.
      Polysumoylated. Sumoylation is enhanced by PIAS family members and desumoylated by AXAM/SENP2. Sumoylation/desumoylation regulates TCF4 transcription activity in the Wnt signaling pathway without altering interaction with CTNNB1 nor binding DNA.
    • 細胞内局在Nucleus > PML body. Diffuse pattern. Colocalizes with SUMO1 and PIAS4 in a subset of PML (promyelocytic leukemia) nuclear bodies.
    • Information by UniProt
    • 参照データベース
    • 別名
      • HMG box transcription factor 4 antibody
      • hTCF 4 antibody
      • hTCF-4 antibody
      • T cell factor 4 antibody
      • T cell specific HMG box antibody
      • T cell specific transcription factor 4 antibody
      • T-cell factor 4 antibody
      • T-cell-specific transcription factor 4 antibody
      • TCF 4 antibody
      • TCF-4 antibody
      • TCF4 antibody
      • TCF7L2 antibody
      • TCF7L2 protein antibody
      • TF7L2_HUMAN antibody
      • Transcription factor 7 like 2 antibody
      • Transcription factor 7 like 2 T cell specific HMG box antibody
      • Transcription factor 7-like 2 antibody
      see all

    Anti-TCF7L2 antibody 画像



    • Predicted band size : 68 kDa

    Anti-TCF7L2 antibody (ab57679) 使用論文

    ab57679 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab57679.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"